MiMedx Group (MDXG) files investor presentation and highlights its value creation strategy
StreetInsider.com Top Tickers, 05/18/2022
Get instant alerts when news breaks on your stocks. Claim your one week free trial for StreetInsider Premium here.
MiMedx Group, Inc. (NASDAQ: MDXG) today filed an investor presentation with the United States Securities and Exchange Commission in connection with its 2022 annual meeting of shareholders, to be held on June 7, 2022. The presentation and other important shareholder documents are available at www.VoteMIMEDX.com.
In the presentation, MIMEDX outlines the significant progress the company has made over the past three years under the leadership of its current management team and provides transparency on a number of shareholder-relevant topics and initiatives, including:
- Long-term value creation strategy: MIMEDX has taken decisive steps to sustain, stabilize and successfully grow the company over the past three years, and has a clear strategy for creating long-term shareholder value. MIMEDX recently announced a third consecutive quarter of double-digit growth for its Advanced Wound Care & Surgical Recovery products, demonstrating strong execution. In addition, the realignment of the company’s internal business structure enables MIMEDX to continue to expand, innovate and drive sustained growth, as well as accelerate the start of trial recruitment into its clinical trial program in knee osteoarthritis.
- Corporate Governance Practices and Board Qualifications: MIMEDX’s Board of Directors has been fully reconstituted since 2019 and is comprised of nine highly qualified directors with the critical skills, life science experience and business acumen to oversee the company’s strategy. The Board of Directors has passed approximately 70 best-practice, shareholder-friendly corporate governance reforms over the past three years and resolved all of the company’s legacy issues, demonstrating its commitment to best-practice governance .
- Executive compensation: MIMEDX executive compensation, determined in partnership with an independent consultant, is based on an organizational and individual performance philosophy and is aligned with shareholder value through performance factors, including revenue growth, and a significant portion of total stock compensation. It sits well within the range of MIMEDX peers and is closely aligned with shareholder interests. For example, in part due to the company’s declining stock price, none of the MIMEDX executives received annual cash bonuses at their 2021 target levels.
|Your vote matters no matter how many or how many shares you own You can vote by Internet, by telephone or by signing and dating the WHITE proxy card and mail it in the envelope provided. If you have any questions about how to vote for your shares or need further assistance, please contact: TOMORROW SODALI [email protected] (203) 658-9400 or Toll Free (800) 662-5200|
Serious news for serious traders! Try StreetInsider.com Premium for free!